Stacie Dusetzina, Ph.D., University of North Carolina Health Care (IMAGE)

University of North Carolina Health Care

Stacie Dusetzina, Ph.D., University of North Carolina Health Care

Caption

Using data from health plan claims for the anti-cancer drug imatinib filed between 2002 to 2011, Stacie B. Dusetzina, Ph.D., research professor at the UNC School of Medicine and Gillings School of Global Public Health and member of the UNC Lineberger Comprehensive Cancer Center, found that patients with higher co-payments were 70 percent more likely to stop taking their cancer treatment and 42 percent more likely to skip doses.

Credit

UNC Lineberger Comprehensive Cancer Center

Usage Restrictions

None

License

Licensed content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.